Clinical trial
A Randomized, Open-label, Fed, Single Dose, Two-way Crossover Study to Evaluate the Pharmacokinetics and Safety of "BR3409" and Co-administration of "BR3409-1" and "BR3409-2" in Healthy Volunteers
NCT06879132 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Fed, Single Dose, Two-way Crossover Study to Evaluate the Pharmacokinetics and Safety of "BR3409" and Co-administration of "BR3409-1" and "BR3409-2" in Healthy Volunteers
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 5, 2024
- Completion date
- December 7, 2024
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes